Analyst Ratings For Agile Therapeutics Inc (NASDAQ:AGRX)
Today, Maxim Group initiated coverage on Agile Therapeutics Inc (NASDAQ:AGRX) with a Buy with a price target of $3.00.
There are 5 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Agile Therapeutics Inc (NASDAQ:AGRX) is Buy with a consensus target price of $3.75 per share, a potential 362.96% upside.
Some recent analyst ratings include
- 11/29/2018-Agile Therapeutics Inc (NASDAQ:AGRX) has coverage initiated with a Buy rating and $3.00 price target
- 3/14/2018-Agile Therapeutics Inc (NASDAQ:AGRX) had its Buy rating reiterated by Noble Financial
- 12/28/2017-Agile Therapeutics Inc (NASDAQ:AGRX) gets downgraded to Neutral by Janney Montgomery Scott
- 12/26/2017-Agile Therapeutics Inc (NASDAQ:AGRX) gets downgraded to Market Perform by William Blair
- 12/22/2017-Agile Therapeutics Inc (NASDAQ:AGRX) had its Buy rating reiterated by Cantor Fitzgerald with a $5.00 price target
- On 7/26/2018 Life Sciences Maste Perceptive, Insider, sold 298,628 with an average share price of $0.30 per share and the total transaction amounting to $89,588.40.
- On 8/25/2017 Alfred Altomari, Chairman, bought 10,000 with an average share price of $3.34 per share and the total transaction amounting to $33,400.00.
- On 8/25/2017 Renee Selman, Insider, bought 7,250 with an average share price of $3.35 per share and the total transaction amounting to $24,287.50.
- On 5/11/2017 Alfred Altomari, Chairman, bought 10,000 with an average share price of $3.51 per share and the total transaction amounting to $35,100.00.
- On 5/11/2017 Renee Selman, Insider, bought 53,333 with an average share price of $3.68 per share and the total transaction amounting to $196,265.44.
- On 1/27/2016 Jay Moorin, Major Shareholder, bought 393,700 with an average share price of $6.35 per share and the total transaction amounting to $2,499,995.00.
- On 6/2/2015 Alfred Altomari, CEO, bought 2,500 with an average share price of $8.73 per share and the total transaction amounting to $21,825.00.
About Agile Therapeutics Inc (NASDAQ:AGRX)
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Recent Trading Activity for Agile Therapeutics Inc (NASDAQ:AGRX)
Shares of Agile Therapeutics Inc closed the previous trading session at 0,81 +0,011 1,41 % with 0.82 shares trading hands.